Vidya Sabale
Research Subjects
Research Interests
Vidya Sabale has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Prafulla Sabale
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, India
16 shared publications - Ashwini Ingole
Department of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, India
3 shared publications - Manasi Jiwankar
Department of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Nagpur, India
3 shared publications Prafulla Sabale
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Mahatma Jyotiba Fuley Shaikshanik Parisar, Nagpur 440 033, Maharashtra, India
3 shared publications- Ali Mujtaba
Center for Health Research, Northern Border University, Arar, Saudi Arabia
2 shared publications - Amol Warokar
Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, India
2 shared publications
Latest Publications
- 3 October 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 220
Coloading of Mangiferin and Capecitabine in Niosomes: A Novel Strategy for Improved Breast Cancer Treatment
- 3 October 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 220
Coloading of Mangiferin and Capecitabine in Niosomes: A Novel Strategy for Improved Breast Cancer Treatment
- Open Access
- 27 August 2026
- Published by Springer Nature in Discover Industrial Chemistry and Materials
- Vol. 1 (1) , 17
Nanohybrid cerasomes as silica lipid carriers for targeted therapeutics
- 27 August 2026
- Published by Springer Nature in Discover Industrial Chemistry and Materials
- Vol. 1 (1) , 17
Open AccessNanohybrid cerasomes as silica lipid carriers for targeted therapeutics
- 8 May 2026
- Published by Bentham Science Publishers Ltd. in Micro and Nanosystems
- Vol. 18
QbD-based Development and Optimization of Dual Drug-loaded Solid Lipid Nanoparticles for Synergistic Anticancer Efficacy
Introduction: Cancer is one of the most widespread diseases worldwide, with chemotherapy as a common treatment, though often limited by severe side effects and multidrug resistance (MDR). Nanocarrier system with co-delivery of drugs can overcome these side effects by reducing toxicity and enabling combination therapy. Methods: In this study, solid lipid nanoparticles (SLNs) were developed for delivering methotrexate (MTX) and silymarin (SYM) using the microemulsion method, followed by sonication, and optimization via a QbD approach. Optimized SLNs were characterized for compatibility, morphology, particle size, entrapment efficiency, drug release, permeability, anticancer activity, and stability. Results: FTIR confirmed the compatibility of SLN components. DSC and XRD confirmed drug encapsulation and reduced crystallinity, while a small particle size (100-200 nm) provided a favourable morphology for targeting via enhanced permeation and retention. Entrapment efficiencies were observed as 92 % (MTX) and 89 % (SYM). In vitro drug release showed a biphasic profile over 12 h, with an initial burst release followed by sustained release. The surface morphology of SLNs was spherical and uniform, as confirmed by FE-SEM. The IC50 value for MTX-SYM-SLNs was significantly lower than that of pure SYM and MTX. SLNs effectively reduced MCF-7 cell viability, with an IC50 of 390 µg/ml. SLNs were observed to be stable. Discussion: SLNs showed nanosize high entrapment, enhanced cytotoxicity, and sustained release for improved delivery. Conclusion: The co-delivery of MTX and SYM via SLNs presents enhanced cytotoxic effect, which may be attributed to improved cellular uptake and synergistic anticancer activity
- 8 May 2026
- Published by Bentham Science Publishers Ltd. in Micro and Nanosystems
- Vol. 18
QbD-based Development and Optimization of Dual Drug-loaded Solid Lipid Nanoparticles for Synergistic Anticancer Efficacy
Introduction: Cancer is one of the most widespread diseases worldwide, with chemotherapy as a common treatment, though often limited by severe side effects and multidrug resistance (MDR). Nanocarrier system with co-delivery of drugs can overcome these side effects by reducing toxicity and enabling combination therapy. Methods: In this study, solid lipid nanoparticles (SLNs) were developed for delivering methotrexate (MTX) and silymarin (SYM) using the microemulsion method, followed by sonication, and optimization via a QbD approach. Optimized SLNs were characterized for compatibility, morphology, particle size, entrapment efficiency, drug release, permeability, anticancer activity, and stability. Results: FTIR confirmed the compatibility of SLN components. DSC and XRD confirmed drug encapsulation and reduced crystallinity, while a small particle size (100-200 nm) provided a favourable morphology for targeting via enhanced permeation and retention. Entrapment efficiencies were observed as 92 % (MTX) and 89 % (SYM). In vitro drug release showed a biphasic profile over 12 h, with an initial burst release followed by sustained release. The surface morphology of SLNs was spherical and uniform, as confirmed by FE-SEM. The IC50 value for MTX-SYM-SLNs was significantly lower than that of pure SYM and MTX. SLNs effectively reduced MCF-7 cell viability, with an IC50 of 390 µg/ml. SLNs were observed to be stable. Discussion: SLNs showed nanosize high entrapment, enhanced cytotoxicity, and sustained release for improved delivery. Conclusion: The co-delivery of MTX and SYM via SLNs presents enhanced cytotoxic effect, which may be attributed to improved cellular uptake and synergistic anticancer activity
- Open Access
- 25 March 2026
- Published by Springer Nature in Discover Chemistry
- Vol. 3 (1)
Development of eco-friendly and sustainable analytical methods for Ritonavir through white analytical chemistry and AQbD approach
- 25 March 2026
- Published by Springer Nature in Discover Chemistry
- Vol. 3 (1)
Open AccessDevelopment of eco-friendly and sustainable analytical methods for Ritonavir through white analytical chemistry and AQbD approach
- 27 February 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 217
Development of Stability-Indicating Green HPTLC Method for Quantitative Analysis of Baricitinib in API and Pharmaceutical Formulation
- 27 February 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 217
Development of Stability-Indicating Green HPTLC Method for Quantitative Analysis of Baricitinib in API and Pharmaceutical Formulation
- 3 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 50
Formulation, Optimization and Pharmacokinetic Evaluation of Mangiferin-loaded Niosomes for Enhanced Breast Cancer Activity
- 3 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 50
Formulation, Optimization and Pharmacokinetic Evaluation of Mangiferin-loaded Niosomes for Enhanced Breast Cancer Activity
- 28 March 2025
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 62 (03) , 26-37
ENHANCING SOLUBILITY AND PERMEABILITY OF HYDROCHLOROTHIAZIDE USING SOLID LIPID NANOPARTICLES
Hydrochlorothiazide, a poorly soluble and also a poorly permeable drug of BCS class IV, was formulated into solid lipid nanoparticles (SLNs) using the microemulsion method. Precirol® ATO 5, Tween® 80 and Kolliphor® P 188 were employed as lipid, surfactant and co-surfactant, respectively. Optimization using 23 factorial design explored lipid concentration (A), surfactant concentration (B) and stirring time (C) as independent variables, and particle size (Y1), % entrapment efficiency (Y2), and drug release (Y3) as responses. FTIR and DSC demonstrated drug-excipient compatibility. The optimized SLNs showed a 12-fold water solubility increase, 94.75±0.0026 % drug content, 91.23±0.29 % entrapment efficiency, 35.06±0.0019 % drug loading and sustained zero order drug release. A permeation study revealed enhanced flux (166.14±0.013µg cm-2h) and permeability coefficient (83.07±0.031 cm h-1) compared to the pure drug. SEM showed uniform, smooth particles, while XRD confirmed the SLN’s amorphous nature. These results show the potential of SLNs to significantly enhance the hydrochlorothiazide’s solubility and permeability.
- 28 March 2025
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 62 (03) , 26-37
ENHANCING SOLUBILITY AND PERMEABILITY OF HYDROCHLOROTHIAZIDE USING SOLID LIPID NANOPARTICLES
Hydrochlorothiazide, a poorly soluble and also a poorly permeable drug of BCS class IV, was formulated into solid lipid nanoparticles (SLNs) using the microemulsion method. Precirol® ATO 5, Tween® 80 and Kolliphor® P 188 were employed as lipid, surfactant and co-surfactant, respectively. Optimization using 23 factorial design explored lipid concentration (A), surfactant concentration (B) and stirring time (C) as independent variables, and particle size (Y1), % entrapment efficiency (Y2), and drug release (Y3) as responses. FTIR and DSC demonstrated drug-excipient compatibility. The optimized SLNs showed a 12-fold water solubility increase, 94.75±0.0026 % drug content, 91.23±0.29 % entrapment efficiency, 35.06±0.0019 % drug loading and sustained zero order drug release. A permeation study revealed enhanced flux (166.14±0.013µg cm-2h) and permeability coefficient (83.07±0.031 cm h-1) compared to the pure drug. SEM showed uniform, smooth particles, while XRD confirmed the SLN’s amorphous nature. These results show the potential of SLNs to significantly enhance the hydrochlorothiazide’s solubility and permeability.
- 11 March 2025
- Published by Bentham Science Publishers Ltd. in Pharmaceutical Nanotechnology
- Vol. 13, 1-21
Advancements in Nanoparticle-Based Targeted Drug Delivery Systems for Breast Cancer
Cancer is a leading cause of death and life-threatening disease globally. It is connected to persistent tissue damage and unregulated cellular proliferation. In females, breast cancer plays a crucial role in death rates. Chemotherapy, alongside surgery, radiation, and hormone therapy, is a first-line treatment, but its non-specific action harms both cancerous and healthy cells, causing severe side effects. The treatment options for breast cancer are based on the disease stage, which spans from stages 0 to IV. To mitigate this issue, novel strategies focusing on specific targets have been introduced in recent times. Advanced nanocarriers are focused on tumor-specific drug delivery using active targeting based on ligand-receptor identification, this approach has the potential to demonstrate enhanced efficacy compared to passive targeting strategies in the context of therapy for human breast cancer. Surface alteration can assist overcome this issue. This overview focuses on modified nano-sized carriers, including liposomes, micelles, polymeric nanocarriers, carbon dots, and gold nanoparticles. It has been studied to improve therapeutics efficacy, bioavailability, and pharmacokinetics features via mechanisms. The primary aim is no longer confined to merely enveloping cancer medications in novel formulations for diverse delivery pathways; instead, the emphasis lies on precise cancer targeting. This review focuses on the stages of breast cancer, obstacles, types of breast cancer therapies, techniques, and various nanocarriers using ligand-mediated drug delivery systems and their mechanisms.
- 11 March 2025
- Published by Bentham Science Publishers Ltd. in Pharmaceutical Nanotechnology
- Vol. 13, 1-21
Advancements in Nanoparticle-Based Targeted Drug Delivery Systems for Breast Cancer
Cancer is a leading cause of death and life-threatening disease globally. It is connected to persistent tissue damage and unregulated cellular proliferation. In females, breast cancer plays a crucial role in death rates. Chemotherapy, alongside surgery, radiation, and hormone therapy, is a first-line treatment, but its non-specific action harms both cancerous and healthy cells, causing severe side effects. The treatment options for breast cancer are based on the disease stage, which spans from stages 0 to IV. To mitigate this issue, novel strategies focusing on specific targets have been introduced in recent times. Advanced nanocarriers are focused on tumor-specific drug delivery using active targeting based on ligand-receptor identification, this approach has the potential to demonstrate enhanced efficacy compared to passive targeting strategies in the context of therapy for human breast cancer. Surface alteration can assist overcome this issue. This overview focuses on modified nano-sized carriers, including liposomes, micelles, polymeric nanocarriers, carbon dots, and gold nanoparticles. It has been studied to improve therapeutics efficacy, bioavailability, and pharmacokinetics features via mechanisms. The primary aim is no longer confined to merely enveloping cancer medications in novel formulations for diverse delivery pathways; instead, the emphasis lies on precise cancer targeting. This review focuses on the stages of breast cancer, obstacles, types of breast cancer therapies, techniques, and various nanocarriers using ligand-mediated drug delivery systems and their mechanisms.
- 20 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 306 (Pt 1) , 141257
Acyl chitosan based self-nanoemulsifying drug delivery system of lipophilic drug with enhanced oral bioavailability and mucoadhesion: Formulation development, optimization and in vitro/in vivo characterization
- 20 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 306 (Pt 1) , 141257
Acyl chitosan based self-nanoemulsifying drug delivery system of lipophilic drug with enhanced oral bioavailability and mucoadhesion: Formulation development, optimization and in vitro/in vivo characterization